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Clinical Question 
Does metformin (Glucophage) therapy reduce the likelihood of obese adolescents developing 
diabetes? 
Evidence-Based Answer 
No studies have addressed the question of whether metformin reduces development of diabetes 
among adolescents who are obese. Metformin treatment in adolescents who are obese can 
modestly reduce risk factors for type 2 diabetes, including elevated body mass index (BMI), 
fasting insulin levels, and fasting glucose levels. (Strength of Recommendation [SOR]: C). 
However, metformin treatment is associated with nausea, abdominal pain, and diarrhea. (SOR: 
A). Because of the limited available data, metformin is not recommended for diabetes prevention 
in adolescents. (SOR: C). 
Evidence Summary 
Overweight and obesity are associated with an increased likelihood of type 2 diabetes, 
hypertension, hyperlipidemia, cardiovascular disease, osteoarthritis, and several other 
conditions.1 Of particular concern is the rapid increase in the prevalence of overweight among 
children, which rose from 5 percent in persons 12 to 19 years of age in 1976 through 1980 to 
17.4 percent in 2003 through 2004.2 Severe childhood overweight (greater than 95 percent of 
BMI for age) is associated with adult obesity and its sequelae. Type 2 diabetes is rapidly 
becoming the most common type of diabetes in children. 
The Diabetes Prevention Program (DPP), a three-year study of 3,234 obese, nondiabetic adults 
with elevated fasting blood glucose, showed that metformin treatment can prevent the 
development of type 2 diabetes. The DPP study also found that drug treatment was less effective 
than lifestyle modification; 58 percent of participants in the lifestyle modification group did not 
develop diabetes compared with 31 percent in the metformin group.3 There are no studies that 
specifically address the use of metformin for the prevention of diabetes among adolescents. 
Three small randomized controlled trials evaluated metformin for the treatment of obesity among 
adolescents. However, the studies are limited by short duration (nine weeks to one year), small 
sample size (22 to 29 patients), and a failure to measure anything other than physiologic end 
points (e.g., BMI, fasting blood sugar levels, fasting insulin levels). Although these studies did 
see modest reductions in BMI (approximately 1 to 2 mg per kg2) and weight (3 to 4 kg), the 
long-term safety and clinical effectiveness of these drugs in adolescents is unknown.4-6 
Furthermore, nausea was a common adverse effect of treatment; in one study, 40 percent of 
treated participants experienced abdominal discomfort or diarrhea.5 
Recommendations from Others 
The American Diabetes Association recommends lifestyle changes and avoiding weight gain for 
diabetes prevention in adolescents.7 There are no professional organizations that endorse the use 
of metformin in adolescents who do not have polycystic ovary syndrome or type 2 diabetes 
mellitus. 
Clinical Commentary 
The use of metformin in adults who are obese helps to reduce weight and to delay the 
development of diabetes. However, compliant patients willing to take a long-term medication 
that may cause nausea are likely to also follow advice about exercise, a reduced-calorie diet, 
smoking cessation, and, if needed, taking blood pressure medication. The real issue in clinical 
practice, therefore, is how to treat those patients who are obese and have little or no genuine 
motivation to make a lifestyle change. A diabetes diagnosis is clearly a marker for increased risk, 
but simply giving medication in the short term to temporarily reduce the blood sugar will likely 
accomplish nothing. What physicians really need to see is evidence regarding how to best 
motivate adolescents who are overweight to adopt a significant long-term lifestyle change; this is 
what will likely result in improved patient-oriented outcomes. 
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